There is a serious worldwide shortage of recombinant factor VIII, a critical blood-clotting protein that hemophilic patients use to prevent and control their bleeds, according to the National ...

Hemophilia A and B coagulation defects, which are caused by deficiencies of Factor VIII and Factor IX, respectively, can be bypassed by administration of recombinant Factor VIIa. However ...

Hemophilia A is a genetic condition that prevents the body from making enough of clotting factor VIII (factor 8). Clotting factors are proteins in the blood that are involved in coagulation (clot ...

Haemophilia A involves a deficiency of clotting factor VIII, Haemophilia B entails a shortage of clotting factor IX, and ...

JW Pharmaceutical commercializes CSA test for Hemlibra patients in South Korea JW Pharmaceutical launches a new hemophilia ...

People with haemophilia A have a shortage of a clotting agent called Factor VIII, while people with haemophilia B do not have enough Factor IX. In the 1970s, a new treatment using donated human ...

A recent study led by MedUni Vienna provides new insights into the mechanisms of coagulation in persons with haemophilia A, ...

Severe Haemophilia A that falls below 1% clotting factor VIII means constant medical attention and treatment; that is the rationale behind developing a gene therapy. Delivering the targeted genes ...

That was before the spectacular success of Hemlibra, a bispecific antibody-based drug that mimics the function of Factor VIII by bridging clotting factors on either side of it in the clotting pathway.

A recent study provides new insights into the mechanisms of coagulation in persons with haemophilia A, the most common form of haemophilia. The research team was able to show that saliva contains ...